MedTrace Logo

Tocotrienol Supplementa as A Senolytic Agent in Middle-aged Adults

NCT07637487 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-06-09

No results posted yet for this study

Summary

The goal of this clinical trial is to determine whether tocotrienol works as a senolytic agent to delay age-related biological changes in middle-aged adults. The study will also evaluate the safety of tocotrienol supplementation. The main questions it aims to answer are:

Does tocotrienol reduce markers of cellular senescence, inflammation, oxidative stress, and mitochondrial dysfunction?

What health changes or medical issues occur in participants taking tocotrienol?

Researchers will compare tocotrienol-rich fraction to a placebo (a look-alike capsule with no active ingredient) to determine whether tocotrienol is effective in modulating aging-related pathways.

Participants will:

Take tocotrienol (200 mg/day) or a placebo daily for 6 months

Attend study visits at baseline, 3 months, and 6 months for clinical assessments and laboratory tests

Undergo blood sampling and health evaluations, including measures of senescence-associated secretory phenotype (SASP), inflammation, oxidative stress, mitochondrial function, vascular health, skin status, cognitive function, body composition, and bone mineral density.

Complete questionnaires related to diet throughout the study period

This study aims to provide clinical evidence on the potential of tocotrienol as a senolytic intervention for promoting healthy aging and reducing the risk of age-related diseases.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Treatment

Each participant will receive 200mg/day of tocotrienol-rich fraction capsules divided into two daily doses

OTHER

Placebo

Participant will receive placebo softgel of 200mg divided into two daily doses

Sponsors & Collaborators

  • Malaysia Palm Oil Board

    collaborator OTHER_GOV

  • Davos Life Science Pte Ltd

    collaborator INDUSTRY

  • National University of Malaysia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-12-19
Completion
2027-01-30

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07637487 on ClinicalTrials.gov